Clinical Trial of Recombinant Hepatitis E Vaccine
A Phase 3, Randomized, Double-blind, Placebo (Hepatitis B Vaccine) Controlled Clinical Trial of Recombinant (E. Coli) Hepatitis E Vaccine
Sponsor: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Listed as NCT01014845, this PHASE3 trial focuses on Hepatitis E and remains completed. Sponsored by Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., it has been updated 9 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jan 2024 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jun 2018 — Aug 2020 [monthly]
Unknown Status PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Aug 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
- Jiangsu Provincial Center for Disease Control and Prevention
- National Institute of Diagnostics and Vaccine Development in infectious disease
- Xiamen Innovax Biotech Co., Ltd
- Xiamen University
For direct contact, visit the study record on ClinicalTrials.gov .